Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

Summary

The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objectives of the study are to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series, and to determine the protection afforded by Gardasil vaccine over time in previously vaccinated adults living with HIV. The clinical hypothesis is that adults with virologically controlled HIV mount a serum antibody response to the nonavalent HPV vaccine that is comparable to HIV negative counterparts. We also postulate that HPV vaccination will provide short-term clinical benefit against HPV infections and disease associated with vaccine genotypes and continuing protection against vaccine genotypes of HPV over time.

Eligibility

Inclusion Criteria:

* HIV seropositive
* immune intact (CD4+ T cell count in peripheral blood \>200 cells/ml)
* HIV controlled (peripheral blood HIV viral load \<1,000 genome copies/mL)
* Stable on antiretroviral regimen for ≥3 months
* Gardasil-9 naive and age ≤45 OR
* documented receipt of 3 doses of Gardasil-4 or Gardasil-9 HPV vaccine

Exclusion Criteria:

* Medical contraindication for vaccination (vaccine-naive arm only)
* Women who are pregnant
* Acute illness
* Taking chronic steroids, \>0.5mg/kg prednisone or equivalent
* Taking immune modulating medications
* Received blood transfusion/blood products within the past 6 months
* Recipients of other vaccine products within the past month
* Inability to provide informed written consent

Conditions8

Locations1 site

Browse More Trials